WorldWide Pulmonary Arterial Hypertension (PAH) Market, Industry / Sector Analysis Report, Regional Outlook & Competitive Market Share & Forecast, 2019 - 2025 (Includes Business Impact of COVID-19)

                                          
Pulmonary Arterial Hypertension Market size is projected to experience significant growth owing to rising geriatric population coupled with increasing incidence rates and prevalence of pulmonary arterial hypertension disorder, government initiatives to develop novel drugs. Prevalence of PAH disorder is growing owing to the factors such as HIV, smoking, changing lifestyle, alcohol, tobacco consumption, and other idiopathic condition.
 

Pulmonary arterial hypertension occurs due to the rise in blood pressure in the small arteries inside lungs. The disease arise in association with several disorder, which includes lung and cardiovascular diseases. The most common primary causes are high blood pressure, connective tissue disorders, coronary artery disorder, congenital heart disorders and blood clots. The indication of disease includes chest ache, breathlessness, dizziness, and fatigue.
 

According to the WHO, high blood pressure is projected to cause 7.5 million death rates across the world. Hypertension is one of the major risk factor for coronary heart disorder, ischemic and hemorrhagic stroke. It also results into peripheral vascular illness, heart failure, renal injury, retinal damage and visual loss. The low awareness levels about the disease and treatment in the undeveloped regions are the restraining factor of the industry.
 

The patent expiry of drugs such as Adcirca, Tyvaso, Tracleer and Letairis is predicted to restraint the revenue share over the forecast timeframe, as their generic forms will be sold at lower prices compared to the branded drugs. Advancement in the treatment of PAH is likely to be a growth prospect for drug manufacturers, as existing drugs are not adequate to meet the therapeutic needs of individuals suffering from disease.
 

The existence of a huge population over 60 years, which has less immunity levels and is more likely come in contact with such disease, which will drive the growth of the industry over the forecast timeframe. While the beginning age for this illness is 45 years, it is commonly observed in the population over 60 years of age. According to WHO and CDC, the prevalence of PAH across the world is estimated to be in the range of 100,000 – 200,000, and around 15 - 50 incidence rates per million people. Hence, the disease is considered as a rare disorder.
 

Rise in the growth of pipeline drugs with increasing awareness levels of the illness in developed countries supported the progress of PAH market size. It is growing moderately owing to the launch of novel pipeline medicines that target different pathways to suppress the indication of disease. Early diagnosis of the disorder has played a key role in number of patients undertaking treatment.
 

The endothelin receptor antagonists contributed for the major revenue share in 2016. The prostacyclin and prostacyclin analogs drug class is likely to grow at fast rate during the forecast period. In December 2013, Orenitram (treprostinil prolonged release drug) and in May 2016, Uptravi (selexipag) was approved by the European Commission. Adempas (riociguat) sGC stimulator is the only approved drug used to cure PAH. In October 2013, the drug Adempas was initially approved by the U.S. FDA.
 

The U.S. pulmonary arterial hypertension market contributed for the highest revenue share in 2016, due to the supportive healthcare structure for the development and delivery of good quality treatment. Increased awareness levels and well organized reimbursement structure lead to excellent diagnosis rate. Furthermore, supportive laws in the U.S. such as the ODA 1983, and Rare Disease Act 2002 enhanced the development of new medicine for the disease. 
 

Asia Pacific is predicted to grow at a significant rate owing to the rapid economic progress, increased population base and enhanced healthcare systems. Economic development in emerging countries is responsible for the development of the region. Furthermore, increased prevalence of disorders such as HIV accounted for the cause of PAH will create immense growth opportunities.
 

Some of the companies operating in the industry include Actelion Pharmaceuticals, United Therapeutics, Pfizer, Arena Pharmaceuticals, Gilead Sciences, Bayer HealthCare, Merck & Co., Reata Pharmaceuticals, GlaxoSmithKline and SteadyMed. The companies are focusing on growth strategies such as geographical expansion, collaboration, launch and development of new product. For instance, in October 2015, Gilead Sciences, the Letairis with Tadalafil used as novel treatment for PAH received approval from U.S. FDA. This helped the firm to upsurge their product penetration in the U.S.